The myasthenia gravis disease treatment market size is expected to reach USD 5.49 billion by 2034, according to a new study by Polaris Market Research. The report “Myasthenia Gravis Disease Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, and Others), Diagnosis, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Myasthenia gravis (MG) is a chronic autoimmune disorder that causes weakness in the skeletal muscles, particularly those that control voluntary movements such as the muscles used for breathing, swallowing, and eye movement. The condition occurs when the body's immune system attacks and disrupts the communication between nerves and muscles by targeting the acetylcholine receptors at the neuromuscular junction. Treatment for myasthenia gravis aims to improve muscle strength, reduce symptoms, and manage the underlying immune response.
The myasthenia gravis disease treatment market demand is driven by various factors such as the rising prevalence of autoimmune disorders, increasing awareness, and advancements in diagnostic tools and therapies. The growing focus on personalized medicine, biologics, and monoclonal antibodies has opened new opportunities for more effective treatments, especially for refractory cases. Ongoing research and clinical trials are further advancing therapeutic options, which is improving patient outcomes. Myasthenia gravis disease treatment market trends such as the increasing use of immunotherapies, technological advancements in diagnostics, and the shift toward precision medicine are shaping the market. Additionally, the expansion of healthcare infrastructure and rising patient advocacy contribute to market growth. The overall market is expected to experience steady growth during the forecast period as new therapies emerge and accessibility improves.
Myasthenia Gravis Disease Treatment Market Report Highlights
By treatment type, the monoclonal antibodies segment dominates the myasthenia gravis disease treatment market share, driven by their targeted action and growing adoption for refractory cases. This segment is expected to register the highest growth rate as innovative biologics continue to emerge, improving patient outcomes.
Based on end use, the hospitals segment remains the largest segment due to their comprehensive care offerings and access to specialized treatments. However, the clinics segment is poised for the highest growth rate, fueled by increased outpatient care preferences and advancements in telemedicine services for myasthenia gravis management.
North America holds the largest share of the myasthenia gravis disease treatment market revenue, driven by advanced healthcare infrastructure and a higher prevalence of the disease. The Asia Pacific market is expected to witness the highest growth rate due to improving healthcare systems, rising awareness about disease treatment, and increasing access to advanced treatments.
A few prominent companies operating in the market include F. Hoffmann-La Roche AG; Novartis AG; Alexion Pharmaceuticals, Inc. (a part of AstraZeneca); and Grifols S.A., all of which have substantial portfolios in neurology and autoimmune disease treatments. Companies such as CSL Behring, UCB S.A., and Takeda Pharmaceutical Company Limited are also important players, contributing with their immunotherapy products and extensive research initiatives.
Polaris Market Research has segmented the Myasthenia Gravis disease treatment market report on the basis of treatment type, diagnosis, end use, and region:
By Treatment Type Outlook (Revenue – USD Billion, 2020–2034)
Cholinesterase Inhibitors
Chronic Immunomodulators
Monoclonal Antibodies
Rapid Immunotherapies
Thymectomy
Others
By Diagnosis Outlook (Revenue – USD Billion, 2020–2034)
Blood Tests
Electrodiagnosis
Edrophonium Test
By End Use Outlook (Revenue – USD Billion, 2020–2034)
Hospitals
Clinics
Others
By Regional Outlook (Revenue – USD Billion, 2020–2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source
- 4. Global Myasthenia Gravis Disease Treatment Market Insights
- 4.1. Myasthenia Gravis Disease Treatment Market – Market Snapshot
- 4.2. Myasthenia Gravis Disease Treatment Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Prevalence of Myasthenia Gravis
- 4.2.1.2. Advancements in Diagnostic Techniques
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Treatment Costs
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry Among Existing Firms (High)
- 4.4. PESTEL Analysis
- 4.5. Myasthenia Gravis Disease Treatment Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. Global Myasthenia Gravis Disease Treatment Market, by Treatment Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 5.3. Cholinesterase Inhibitors
- 5.3.1. Global Myasthenia Gravis Disease Treatment Market, by Cholinesterase Inhibitors, by Region, 2020–2034 (USD Billion)
- 5.4. Chronic Immunomodulators
- 5.4.1. Global Myasthenia Gravis Disease Treatment Market, by Chronic Immunomodulators, by Region, 2020–2034 (USD Billion)
- 5.5. Monoclonal Antibodies
- 5.5.1. Global Myasthenia Gravis Disease Treatment Market, by Monoclonal Antibodies, by Region, 2020–2034 (USD Billion)
- 5.6. Rapid Immunotherapies
- 5.6.1. Global Myasthenia Gravis Disease Treatment Market, by Rapid Immunotherapies, by Region, 2020–2034 (USD Billion)
- 5.7. Thymectomy
- 5.7.1. Global Myasthenia Gravis Disease Treatment Market, by Thymectomy, by Region, 2020–2034 (USD Billion)
- 5.8. Others
- 5.8.1. Global Myasthenia Gravis Disease Treatment Market, by Others, by Region, 2020–2034 (USD Billion)
- 6. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 6.3. Blood Tests
- 6.3.1. Global Myasthenia Gravis Disease Treatment Market, by Blood Tests, by Region, 2020–2034 (USD Billion)
- 6.4. Electrodiagnosis
- 6.4.1. Global Myasthenia Gravis Disease Treatment Market, by Electrodiagnosis, by Region, 2020–2034 (USD Billion)
- 6.5. Edrophonium Test
- 6.5.1. Global Myasthenia Gravis Disease Treatment Market, by Edrophonium Test, by Region, 2020–2034 (USD Billion)
- 7. Global Myasthenia Gravis Disease Treatment Market, by End Use
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 7.3. Hospitals
- 7.3.1. Global Myasthenia Gravis Disease Treatment Market, by Hospitals, by Region, 2020–2034 (USD Billion)
- 7.4. Clinics
- 7.4.1. Global Myasthenia Gravis Disease Treatment Market, by Clinics, by Region, 2020–2034 (USD Billion)
- 7.5. Others
- 7.5.1. Global Myasthenia Gravis Disease Treatment Market, by Others, by Region, 2020–2034 (USD Billion)
- 8. Global Myasthenia Gravis Disease Treatment Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Myasthenia Gravis Disease Treatment Market Assessment, by Geography, 2020–2034 (USD Billion)
- 8.3. Myasthenia Gravis Disease Treatment Market – North America
- 8.3.1. North America: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.3.2. North America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.3.3. North America: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.3.4. Myasthenia Gravis Disease Treatment Market – US
- 8.3.4.1. US: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.3.4.2. US: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.3.4.3. US: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.3.5. Myasthenia Gravis Disease Treatment Market – Canada
- 8.3.5.1. Canada: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.3.5.2. Canada: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.3.5.3. Canada: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.4. Myasthenia Gravis Disease Treatment Market – Europe
- 8.4.1. Europe: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.4.2. Europe: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.4.3. Europe: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.4.4. Myasthenia Gravis Disease Treatment Market – UK
- 8.4.4.1. UK: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.4.4.2. UK: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.4.4.3. UK: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.4.5. Myasthenia Gravis Disease Treatment Market – France
- 8.4.5.1. France: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.4.5.2. France: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.4.5.3. France: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.4.6. Myasthenia Gravis Disease Treatment Market – Germany
- 8.4.6.1. Germany: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.4.6.2. Germany: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.4.6.3. Germany: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.4.7. Myasthenia Gravis Disease Treatment Market – Italy
- 8.4.7.1. Italy: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.4.7.2. Italy: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.4.7.3. Italy: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.4.8. Myasthenia Gravis Disease Treatment Market – Spain
- 8.4.8.1. Spain: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.4.8.2. Spain: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.4.8.3. Spain: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.4.9. Myasthenia Gravis Disease Treatment Market – Netherlands
- 8.4.9.1. Netherlands: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.4.9.2. Netherlands: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.4.9.3. Netherlands: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.4.10. Myasthenia Gravis Disease Treatment Market – Russia
- 8.4.10.1. Russia: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.4.10.2. Russia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.4.10.3. Russia: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.4.11. Myasthenia Gravis Disease Treatment Market – Rest of Europe
- 8.4.11.1. Rest of Europe: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.4.11.2. Rest of Europe: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.4.11.3. Rest of Europe: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.5. Myasthenia Gravis Disease Treatment Market – Asia Pacific
- 8.5.1. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.5.2. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.5.3. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.5.4. Myasthenia Gravis Disease Treatment Market – China
- 8.5.4.1. China: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.5.4.2. China: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.5.4.3. China: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.5.5. Myasthenia Gravis Disease Treatment Market – India
- 8.5.5.1. India: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.5.5.2. India: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.5.5.3. India: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.5.6. Myasthenia Gravis Disease Treatment Market – Malaysia
- 8.5.6.1. Malaysia: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.5.6.2. Malaysia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.5.6.3. Malaysia: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.5.7. Myasthenia Gravis Disease Treatment Market – Japan
- 8.5.7.1. Japan: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.5.7.2. Japan: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.5.7.3. Japan: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.5.8. Myasthenia Gravis Disease Treatment Market – Indonesia
- 8.5.8.1. Indonesia: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.5.8.2. Indonesia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.5.8.3. Indonesia: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.5.9. Myasthenia Gravis Disease Treatment Market – South Korea
- 8.5.9.1. South Korea: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.5.9.2. South Korea: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.5.9.3. South Korea: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.5.10. Myasthenia Gravis Disease Treatment Market – Australia
- 8.5.10.1. Australia: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.5.10.2. Australia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.5.10.3. Australia: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.5.11. Myasthenia Gravis Disease Treatment Market – Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.5.11.2. Rest of Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.5.11.3. Rest of Asia Pacific: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.6. Myasthenia Gravis Disease Treatment Market – Middle East & Africa
- 8.6.1. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.6.2. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.6.3. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.6.4. Myasthenia Gravis Disease Treatment Market – Saudi Arabia
- 8.6.4.1. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.6.4.2. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.6.4.3. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.6.5. Myasthenia Gravis Disease Treatment Market – UAE
- 8.6.5.1. UAE: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.6.5.2. UAE: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.6.5.3. UAE: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.6.6. Myasthenia Gravis Disease Treatment Market – Israel
- 8.6.6.1. Israel: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.6.6.2. Israel: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.6.6.3. Israel: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.6.7. Myasthenia Gravis Disease Treatment Market – South Africa
- 8.6.7.1. South Africa: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.6.7.2. South Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.6.7.3. South Africa: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.6.8. Myasthenia Gravis Disease Treatment Market – Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.6.8.2. Rest of Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.6.8.3. Rest of Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.7. Myasthenia Gravis Disease Treatment Market – Latin America
- 8.7.1. Latin America: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.7.2. Latin America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.7.3. Latin America: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.7.4. Myasthenia Gravis Disease Treatment Market – Mexico
- 8.7.4.1. Mexico: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.7.4.2. Mexico: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.7.4.3. Mexico: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.7.5. Myasthenia Gravis Disease Treatment Market – Brazil
- 8.7.5.1. Brazil: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.7.5.2. Brazil: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.7.5.3. Brazil: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.7.6. Myasthenia Gravis Disease Treatment Market – Argentina
- 8.7.6.1. Argentina: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.7.6.2. Argentina: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.7.6.3. Argentina: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 8.7.7. Myasthenia Gravis Disease Treatment Market – Rest of Latin America
- 8.7.7.1. Rest of Latin America: Myasthenia Gravis Disease Treatment Market, by Treatment Type, 2020–2034 (USD Billion)
- 8.7.7.2. Rest of Latin America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2020–2034 (USD Billion)
- 8.7.7.3. Rest of Latin America: Myasthenia Gravis Disease Treatment Market, by End Use, 2020–2034 (USD Billion)
- 9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
- 10. Company Profiles
- 10.1. Alexion Pharmaceuticals, Inc. (a part of AstraZeneca)
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Argenx SE
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Catalyst Pharmaceuticals, Inc.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. CSL Behring
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. F. Hoffmann-La Roche AG
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Grifols S.A.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Immunovant, Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Johnson & Johnson Services, Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Novartis AG
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Takeda Pharmaceutical Company Limited
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. UCB S.A.
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook